MTRC is pleased to announce the release of its latest White Paper: "General Market Access Landscape for Health Apps in Europe". This document provides a structured overview of the reimbursement landscape for health apps in three major European countries: England, France, and Germany.

In March-April 2025, Health Technology Wales (HTW) accomplished one full appraisal of permanent implant brachytherapy devices for unresectable pancreatic cancer. Five Med Tech-related Topic Exploration Reports were published (on superior rectal artery embolization, glucose monitoring systems in neonates, gender-affirming surgery, telemetric intracranial pressure monitoring, tumor-profiling tests to guide bisphosphonate treatment in cancer).

Meet MTRC’s Senior Reimbursement Consultant, Julia Mazur, at the Pharma 4.0 - Digital Healthcare Conference in Berlin. Visit us at Booth #9 to explore tailored solutions in market access, health economics, and evidence synthesis for complex MedTech challenges. Don’t miss Dr. Borisenko’s expert talk on the reimbursement of digital technologies in Europe on 22 May at 10:50 AM.

MTRC is pleased to announce the release of its latest White Paper: "Case study: Market Access Pathway for Preeclampsia Predictive Tests in Germany and Norway". This document provides a detailed case study on how developers of IVD tests can effectively navigate reimbursement pathways in key European markets using the examples of pathways in Germany and Norway.

On May 01, 2025, the Dutch Healthcare Authority (NZa) published the first release of the 2026 DRG package (RZ26a). Three new procedure codes, seven new supplementary payments (OZPs), one new diagnosis code, and two new DRGs will be implemented across in-vitro diagnostics, obstetrics and gynecology, neurology and neurosurgery, cardiovascular and other technology groups.

In April 2025, the HTA body of Tuscany Regional Healthcare published six rapid HTA reports (five new assessments and one reassessment) of medical devices in the cardiovascular, peripheral vascular, endoscopy, and dermatology fields.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, Dijk et al. piloted the CHEQUE tool in the context of systematic reviews of health economic studies in medical education, aiming to assess its usability and inform future improvements. The authors applied CHEQUE to 21 economic evaluations, uncovering a wide range in quality scores (18%‒94%) and a positive correlation between methodological rigor and reporting standards. The study highlighted CHEQUE’s value as a structured assessment tool but also pointed to the need for refinements to reduce complexity and enhance clarity.

On April 30, 2025, the National Association of Statutory Health Insurance Physicians (KBV) announced that it had reached an agreement with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) on the further expansion of the Hybrid DRG catalog in 2026. The decision was made by the extended Evaluation Committee, as no consensus could be reached with the German Hospital Federation (DKG).

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Freitag et al. explored negotiation strategies for pricing and reimbursement of prescription-based mHealth apps (DiGA) in Germany. Based on 16 expert interviews, the authors introduced a four-step framework detailing price determination, payment conditions, payment modalities, and negotiation governance. Statutory insurers expressed a preference for usage-based pricing, while a value-based care model was identified as delivering the greatest patient benefit.

In April 2025, the National Institute for Health and Care Research (NIHR) in England released five Med Tech-related assessments in its HTA Journal, which concerned the evaluation of prognostic models of metastasis in colorectal cancer, assessment of e-Health platform for low back pain and the results of the “CONtact TrAcing in Care homes using digital Technology” trial. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS, and informs NICE guidance.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Pannelay et al. explored the evolving challenges of implementing the EU Health Technology Assessment Regulation, highlighting the burden of aligning national PICO requirements across Member States. The study showed that up to 720 evidence analyses per product may be required ‒ covering various permutations of population, comparator, and outcome ‒ raising serious concerns about feasibility and submission quality. The article also presented a user guide for applying generalized cost-effectiveness analysis to better capture societal value and examined the ongoing debate over NICE’s implementation of the severity modifier tool in the UK.

The French National Authority for Health (HAS) released new recommendations regarding the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the April 2025 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Eleven favorable opinions were published concerning the registration of new devices or modifying conditions/indications for existing ones in the LPPR List. The recommendations relate to devices in the fields of endocrine, e-health, neuromodulation, peripheral vascular, and medical aids.